Daily news and information for physicians in a range of specialties and practice settings.
Investigative drug DB102 will be assessed in approximately 200 patients with newly diagnosed glioblastoma in a Denovo-led phase 2b trial.
Aleksandra Rachitskaya, MD, of Cole Eye Institute, discusses a presentation she led at AAO 2019 on novel imaging and surgical techniques. 
A new study has found that receiving or not receiving topical antibiotics following cataract surgery had no impact on the development of endophthalmitis. 
In a phse 3b study, 75% of patients using HTX-011 were discharged without opioids following a total knee arthroplasty.
A phase 1b study, which was presented by Charles Wykoff, MD, PhD, at AAO 2019, found the novel anti-VEGF therapy KSI-301 shows promise for treating a slew of retinal diseases.
The results of a new survey regarding quality of care for end stage renal disease patients raise questions about how to improve the quality of end-of-life care.
The new transdermal patch offers a new delivery option for a well-established schizophrenia treatment.
Louis Pasquale, MD, professor of medicine at Icahn School of Medicine at Mount Sinai, discusses how technology and artificial intelligence has been embraced by ophthalmology.
A pair of surveys show the majority of patients suffering from Parkinson disease would be willing to take CBD to manage psychosis symptoms if it is proven safe and effective.
A presentation at AAO 2019 highlighted the ability of the EyeArt screening system to detect diabetic retinopathy with 95.5% sensitivity. 
Copyright© MD Magazine 2006-2019 Intellisphere, LLC. All Rights Reserved.